Pharmacokinetics of Hoasca alkaloids in healthy humans - PubMed (original) (raw)
Pharmacokinetics of Hoasca alkaloids in healthy humans
J C Callaway et al. J Ethnopharmacol. 1999 Jun.
Abstract
N,N-Dimethyltryptamine (DMT), harmine, harmaline and tetrahydroharmine (THH) are the characteristic alkaloids found in Amazonian sacraments known as hoasca, ayahuasca, and yajè. Such beverages are characterized by the presence of these three harmala alkaloids, where harmine and harmaline reversibly inhibit monoamine oxidase A (MAO-A) while tetrahydroharmine weakly inhibits the uptake of serotonin. Together, both actions increase central and peripheral serotonergic activity while facilitating the psychoactivity of DMT. Though the use of such 'teas' has be known to western science for over 100 years, little is known of their pharmacokinetics. In this study, hoasca was prepared and administered in a ceremonial context. All four alkaloids were measured in the tea and in the plasma of 15 volunteers, subsequent to the ingestion of 2 ml hoasca/kg body weight, using gas (GC) and high pressure liquid chromatographic (HPLC) methods. Pharmacokinetic parameters were calculated and peak times of psychoactivity coincided with high alkaloid concentrations, particularly DMT which had an average Tmax of 107.5 +/- 32.5 min. While DMT parameters correlated with those of harmine, THH showed a pharmacokinetic profile relatively independent of harmine's.
Similar articles
- Metabolism and disposition of N,N-dimethyltryptamine and harmala alkaloids after oral administration of ayahuasca.
Riba J, McIlhenny EH, Valle M, Bouso JC, Barker SA. Riba J, et al. Drug Test Anal. 2012 Jul-Aug;4(7-8):610-6. doi: 10.1002/dta.1344. Epub 2012 Apr 19. Drug Test Anal. 2012. PMID: 22514127 - Quantitation of N,N-dimethyltryptamine and harmala alkaloids in human plasma after oral dosing with ayahuasca.
Callaway JC, Raymon LP, Hearn WL, McKenna DJ, Grob CS, Brito GS, Mash DC. Callaway JC, et al. J Anal Toxicol. 1996 Oct;20(6):492-7. doi: 10.1093/jat/20.6.492. J Anal Toxicol. 1996. PMID: 8889686 - Human pharmacology of ayahuasca: subjective and cardiovascular effects, monoamine metabolite excretion, and pharmacokinetics.
Riba J, Valle M, Urbano G, Yritia M, Morte A, Barbanoj MJ. Riba J, et al. J Pharmacol Exp Ther. 2003 Jul;306(1):73-83. doi: 10.1124/jpet.103.049882. Epub 2003 Mar 26. J Pharmacol Exp Ther. 2003. PMID: 12660312 Clinical Trial. - Toxicokinetics and Toxicodynamics of Ayahuasca Alkaloids N,_N_-Dimethyltryptamine (DMT), Harmine, Harmaline and Tetrahydroharmine: Clinical and Forensic Impact.
Brito-da-Costa AM, Dias-da-Silva D, Gomes NGM, Dinis-Oliveira RJ, Madureira-Carvalho Á. Brito-da-Costa AM, et al. Pharmaceuticals (Basel). 2020 Oct 23;13(11):334. doi: 10.3390/ph13110334. Pharmaceuticals (Basel). 2020. PMID: 33114119 Free PMC article. Review. - Risk assessment of ritual use of oral dimethyltryptamine (DMT) and harmala alkaloids.
Gable RS. Gable RS. Addiction. 2007 Jan;102(1):24-34. doi: 10.1111/j.1360-0443.2006.01652.x. Addiction. 2007. PMID: 17207120 Review.
Cited by
- A Phase 1 single ascending dose study of pure oral harmine in healthy volunteers.
Ables JL, Israel L, Wood O, Govindarajulu U, Fremont RT, Banerjee R, Liu H, Cohen J, Wang P, Kumar K, Lu G, DeVita RJ, Garcia-Ocaña A, Murrough JW, Stewart AF. Ables JL, et al. J Psychopharmacol. 2024 Oct;38(10):911-923. doi: 10.1177/02698811241273772. Epub 2024 Sep 20. J Psychopharmacol. 2024. PMID: 39301926 Clinical Trial. - Neurobiological research on N,N-dimethyltryptamine (DMT) and its potentiation by monoamine oxidase (MAO) inhibition: from ayahuasca to synthetic combinations of DMT and MAO inhibitors.
Egger K, Aicher HD, Cumming P, Scheidegger M. Egger K, et al. Cell Mol Life Sci. 2024 Sep 10;81(1):395. doi: 10.1007/s00018-024-05353-6. Cell Mol Life Sci. 2024. PMID: 39254764 Free PMC article. Review. - Ayahuasca: A review of historical, pharmacological, and therapeutic aspects.
Ruffell SGD, Crosland-Wood M, Palmer R, Netzband N, Tsang W, Weiss B, Gandy S, Cowley-Court T, Halman A, McHerron D, Jong A, Kennedy T, White E, Perkins D, Terhune DB, Sarris J. Ruffell SGD, et al. PCN Rep. 2023 Oct 2;2(4):e146. doi: 10.1002/pcn5.146. eCollection 2023 Dec. PCN Rep. 2023. PMID: 38868739 Free PMC article. Review. - Long-term ayahuasca use is associated with preserved global cognitive function and improved memory: a cross-sectional study with ritual users.
Fonseca AM, Dos Santos RG, de Medeiros LS, Veiga TAM, Cassas F, Bruniera CP, Rossi GN, Bouso JC, Hallak JEC, Santos FP, Paranhos BAPB, Yonamine M, Rodrigues E. Fonseca AM, et al. Eur Arch Psychiatry Clin Neurosci. 2024 May 23. doi: 10.1007/s00406-024-01817-9. Online ahead of print. Eur Arch Psychiatry Clin Neurosci. 2024. PMID: 38780800 - Long-term benefits to psychological health and well-being after ceremonial use of Ayahuasca in Middle Eastern and North African immigrants and refugees.
Lowe MX, Kettner H, Jolly DRP, Carhart-Harris RL, Jackson H. Lowe MX, et al. Front Psychiatry. 2024 Apr 10;15:1279887. doi: 10.3389/fpsyt.2024.1279887. eCollection 2024. Front Psychiatry. 2024. PMID: 38666090 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous